Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial
NJ Samadder, DW Neklason, KM Boucher, KR Byrne… - Jama, 2016 - jamanetwork.com
Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased
risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal
neoplasia is difficult and chemoprevention has not been successful. Objective To evaluate
the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in
patients with FAP. Design, Setting, and Participants Double-blind, randomized, placebo-
controlled trial, enrolling 92 participants with FAP, conducted from July 2010 through June …
risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal
neoplasia is difficult and chemoprevention has not been successful. Objective To evaluate
the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in
patients with FAP. Design, Setting, and Participants Double-blind, randomized, placebo-
controlled trial, enrolling 92 participants with FAP, conducted from July 2010 through June …